Drugs / TAK-020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02723201 | Apr → Aug 2016 | — | Takeda | Completed | Mixed |
| Phase 1 | NCT02413255 | Mar 2015 → May 2017 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02413255 ↗ |
| Modality | Small molecule | — CHEMBL5073622 ↗ |
| Route | Oral | “TAK-020 0.1 mg, solution, orally once on Day 1.” NCT02413255 ↗ |